Molecular remission of chronic myeloid leukaemia following a non- myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect

British Journal of Haematology

Volumn 107, Issue 2, 1999, Pages 396-400

  Childs, R ^a   Epperson, D ^a   Bahceci, E ^a   Clave, E ^a   Barrett, J ^a,b  

^a Hematology Branch   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Chronic myeloid leukaemia; Cyclophosphamide; Fludarabine; Graft versus leukaemia effect

Indexed keywords

ADULT; ALLOTRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CELL LINEAGE; CHRONIC MYELOID LEUKEMIA; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARYOTYPE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIDARABINE;

EID: 0032734504     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01706.x     Document Type: Article

References (19)

1. Agarwal, R., Doren, S., Hicks, B. & Dunbar, C.E. (1995) Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood, 85, 1306-1312.
2. Barrett, A.J. & Malkovska, V. (1996) Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. British Journal of Haematology, 93, 754-761.
3. Carella, A., Lerma, E., Corsetti, M.T., Dejana, A., Celesti, L., Casarino, L., De Stefano, F. & Frassoni, F. (1998) Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. British Journal of Haematology, 103, 565-567.
4. Carella, A.M., Lerma, E., Corsetti, M.T., Dejana, A., Basta, P., Vassallo, F., Abate, M., Soracco, M., Benvenuto, F., Figari, O., Podesta, M., Piaggio, G., Ferrara, R., Sessarego, M., Parodi, C., Pizzuti, M., Rubagotti, A., Occhini, D. & Frassoni, F. (1999) Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood, 93, 1534-1539.
5. Castelitz, M., Link, H., Hein, R., Maschek, H., Boker, K., Poliwoda, H. & Manns, M.P. (1997) Hepatitis B associated liver failure following bone marrow transplantation. Journal of Hepatology, 27, 572-577.
6. Childs, R., Clave, E., Contentin, N., Bahceci, E. & Barrett, A.J. (1999) Full donor T lymphocyte chimerism predicts for graft-vs-host disease, graft-vs-marrow and graft-vs-malignancy effects following a non-myeloablative preparative regimen. Blood, in press.
7. Clift, R.A. & Anasetti, C. (1997) Allografting for chronic myeloid leukaemia. Baillieres Clinical Haematology, 10, 319-336.
8. Giralt, S., Estey, E., Albitar, M., van Biesen, K., Rondori, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., Claxton, D., Andersson, B., Beran, M., Przepiorka, D., Koller, C., Kornblau, S., Korbling, M., Keating, M., Kantarjian, H. & Champlin, R. (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 89, 12-20.
9. Goldman, J.M. (1997) Treatment of chronic myeloid leukaemia: some topical questions. Bailliere's Clinical Haematology. 10, 405-421.
10. Gratwohl, A., Hermans, J., Goldman, J.M., Arcese, W., Carreras, E., Devergie, A., Frassoni, F., Gahrton, G., Kolb, H.J., Niederwieser, D., Ruutu, T., Vernant, J.P., de Witte, T. & Apperley, J. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 352, 1087-1092.
11. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.-J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, F.E. & Bortin, M.M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555-556.
12. Khouri, I.F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A. & Champlin, R. (1998) Transplant lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancy. Journal of Clinical Oncology, 8, 2817-2824.
13. Kolb, H.-J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jocobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonk, L., Niederwieser, D., van Rhee, F., Mittermuller, J., de Witte, T., Holler, E. & Ansari, H. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041-2050.
14. Landman-Parker, J., Socie, G., Petit, T., Raynal, B., Bourhis, J.H., Pico, J. & Brison, O. (1994) Detection of recipient cells after non T-cell depleted bone marrow transplantation for leukemia by PCR amplification of minisatellites or of a Y chromosome marker has a different prognostic value. Leukemia, 8, 1989-1994.
15. + donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood, 86, 3236-3240.
16. Molldrem, J.J., Clave, E., Jiang, Y.Z., Mavroudis, D., Raptis, A., Hensel, N., Agarwala, V. & Barrett, A.J. (1997) Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood, 90, 2529-2534.
17. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or. R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
18. van Rhee, F., Szydlo, R.M., Hermans, J., Devergie, A., Frassoni, F., Arcese, W., de Witte, T., Kolb, H.J., Niederwiser, D., Jacobsen, N., Gahrton, G., Bandini, G., Carreras, E., Bacigalupo, A., Michallet, M, Ruutu, T., Reiffers, J., Goldman, J.M., Apperley, J. & Gratwohl, A. (1997) Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone. Marrow Transplantation, 20, 553-560.
19. Verfaillie, C.M., Bhatia, R., Miller, W., Mortari, F., Roy, V., Burger, S., McCullough, J., Stieglbauer, K., Dewald, G., Heimfeld, S., Miller, J.S. & McGlave, P.B. (1996) BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood, 87, 4770-4779.